کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3132178 | 1584125 | 2015 | 9 صفحه PDF | دانلود رایگان |
Pain after third molar extraction has been considered the most suitable pharmaceutical model to evaluate acute pain. This study aimed to evaluate the pre-emptive analgesic/anti-inflammatory efficacy of etoricoxib 120 mg following mandibular third molar surgery. A split-mouth, randomized, triple-blind, placebo-controlled study was conducted with patients undergoing the surgical removal of mandibular third molars. All volunteers were allocated randomly to receive either etoricoxib 120 mg or placebo 1 h preoperatively, and inflammatory events were evaluated. An estimated sample of 18 surgical units per group was required based on a pilot study (95% confidence level and 80% statistical power). Rescue medication was analyzed by Kaplan–Meier method through log-rank Mantel–Cox test and Pearson linear correlation (P < 0.05). Pre-emptive etoricoxib reduced postoperative pain scores significantly in comparison to placebo (P < 0.001), with a pain score peak at 6 h after surgery (P < 0.001). The mean rescue medication consumption was lower in the etoricoxib group compared to the placebo group over the study period (P < 0.05). There was no statistically significant difference between groups related to swelling and trismus. The pre-emptive administration of etoricoxib 120 mg significantly reduced the postoperative pain intensity and the need for rescue medication, but did not reduce swelling or trismus.
Journal: International Journal of Oral and Maxillofacial Surgery - Volume 44, Issue 9, September 2015, Pages 1166–1174